Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Alliances symbols : Azn save search
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
Published: 2023-09-11 (Crawled : 13:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -3.31%
H: 1.02%
C: 0.97%
enhertu lung cancer tumor trial
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
Published: 2023-05-12 (Crawled : 21:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.29%
H: 0.81%
C: -0.29%
lm-305 drug antibody license global agreement
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
Published: 2023-03-06 (Crawled : 14:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.01%
H: 0.59%
C: 0.03%
enhertu tumor trial
SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development
Published: 2023-02-13 (Crawled : 14:20) - biospace.com/
SOPH | $4.93 2.71% 2.64% 51K
|
|
| O: 18.84%
H: 0.0%
C: -9.76%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.51%
H: 1.81%
C: 1.72%
partnership drug cancer
Resilience to Establish a Biomanufacturing Partnership with AstraZeneca and Purchase AstraZeneca’s Manufacturing Site in West Chester, Ohio
Published: 2022-11-29 (Crawled : 20:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.93%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.21%
H: 0.16%
C: -0.41%
partnership
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research
Published: 2022-10-27 (Crawled : 12:00) - biospace.com/
NVTA | $0.019 0.0% 22M
|
Health Services
|
| O: 0.6%
H: 1.8%
C: -8.62%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: -0.12%
partnership rare research cancer
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
Published: 2022-08-01 (Crawled : 23:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.39%
H: 0.0%
C: -0.9%
AVTX | $11.71 -2.5% -2.56% 68K
|
Manufacturing
|
| O: 4.72%
H: 10.08%
C: -4.51%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.44%
H: 0.53%
C: -1.31%
il-18 therapeutics
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
Published: 2022-07-25 (Crawled : 12:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.43%
H: 0.39%
C: -0.04%
enhertu granted review cancer her2- her2 metastatic breast cancer
GRAIL Announces Strategic Collaboration With AstraZeneca to Develop Companion Diagnostic Tests to Enable the Treatment of Early-Stage Cancer
Published: 2022-06-02 (Crawled : 17:00) - biospace.com/
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
|
| O: -0.03%
H: 5.85%
C: 5.7%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
treatment collaboration diagnostic cancer test
Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca
Published: 2022-05-16 (Crawled : 11:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.52%
H: 0.0%
C: 0.0%
collaboration license
AstraZeneca Joins Accumulus Synergy as a Sponsor to Accelerate the Delivery of Medicines to Patients
Published: 2022-05-12 (Crawled : 14:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -2.18%
H: 1.85%
C: 1.55%
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Published: 2022-05-05 (Crawled : 12:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: -1.2%
enhertu approved cancer breast cancer her2- her2 metastatic breast cancer
AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers
Published: 2022-02-22 (Crawled : 21:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 3.24%
H: 0.18%
C: -1.6%
partnership program respiratory one
Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy
Published: 2021-12-14 (Crawled : 07:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
covid-19 partnership covid therapy cancer
SAGA Diagnostics enters into an assay development agreement with AstraZeneca
Published: 2021-11-02 (Crawled : 18:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.85%
H: 0.0%
C: 0.0%
diagnostics diagnostic
Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.11%
H: 0.03%
C: -0.27%
lung cancer collaboration cancer trial initiated keytruda
Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline
Published: 2021-08-05 (Crawled : 21:00) - biospace.com/
SRRA | $54.99 0.04% 0.0%
|
Health Technology
|
| O: 0.0%
H: 5.03%
C: 3.82%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.48%
H: 0.46%
C: 0.43%
fibrosis license
Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca
Published: 2021-07-19 (Crawled : 13:15) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.62%
H: 0.78%
C: 0.07%
ARDS | $0.0615 2.82% 410K
|
Health Technology
|
| O: -0.69%
H: 2.94%
C: -12.59%
antibody license phase 3
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
Published: 2021-07-08 (Crawled : 14:15) - biospace.com/
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: 14.31%
H: 0.24%
C: -4.53%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.52%
H: 0.37%
C: -0.32%
license
Proteros Enters Into Oncology Collaboration and License Agreement With AstraZeneca
Published: 2021-06-02 (Crawled : 11:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.66%
H: 0.62%
C: 0.39%
collaboration license
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.